Alzheimer’s disease
This week’s highlights in neurological diseases include Acadia receiving a CRL for its ADP drug, Sosei and Neurocrine’s schizophrenia drug study moving on to Phase II.
This week, drugs developed by Neurocrine Biosciences, Akebia, Eliem and Athira all failed to meet expectations in clinical trials.
Researchers have found that two common viruses—the varicella zoster and herpes simplex viruses—likely constitute a pathway that leads to Alzheimer’s disease.
Roche signed a big $6 billion-plus collaboration deal with Poseida on blood cancers while its partner, AC Immune, parsed failed data on an Alzheimer’s drug to suggest a positive spin.
The annual Alzheimer’s Association International Conference (AAIC) is running from July 31-August 4 at the San Diego Convention Center and online. Here are some of the highlights presented so far.
The ongoing AAIC 2022 in San Diego has delivered positive news for the AD space. We look at updates from Vivoryon, Anavex and Argentinian scientists below.
The data used to support the argument that Aβ*56 is responsible for the Alzheimer’s Disease hallmark of memory loss appears to have been fabricated or heavily tampered with.
A new study published in Frontiers in Aging Neuroscience by researchers at Tufts University further supports the theory that there’s a link between gum disease and Alzheimer’s.
Researchers point out that antibodies against amyloid are still considered an essential approach to treating Alzheimer’s, but the leading risk factor for sporadic AD is aging.
In a filing with the SEC, Abbvie’s decision to terminate came after the two firms jointly conducted a review of their next steps for the drug.
PRESS RELEASES